coxsacki
viru
antivir
properti
mainli
explain
virucid
mechan
moreov
mlt
protect
mice
challeng
lethal
dose
pathogen
influenza
virus
therefor
result
provid
evid
bv
mlt
could
potenti
sourc
promis
antivir
agent
especi
develop
broad
spectrum
antivir
agent
massiv
growth
human
popul
immens
rise
urban
drastic
chang
global
environ
improv
connect
worldwid
term
better
transport
facil
led
emerg
reemerg
viral
diseas
human
popul
li
et
al
outbreak
mani
rna
virus
still
lead
caus
morbid
mortal
worldwid
popul
mani
antivir
agent
divers
virus
report
howev
effect
antivir
agent
specif
target
rna
virus
sarscov
influenza
measl
shortag
due
genet
variat
viru
lack
approv
univers
recommend
therapi
wen
et
al
lorin
et
al
triggiani
et
al
henc
global
requir
continu
develop
new
antivir
agent
especi
natur
sourc
provid
sever
altern
control
prevent
manag
spread
diseas
caus
rna
dna
virus
number
compound
deriv
natur
sourc
report
numer
biolog
activ
thu
consid
potenti
sourc
variou
modern
pharmaceut
includ
antivir
agent
jacob
coyn
kim
et
al
weeratunga
et
al
bee
venom
bv
honey
bee
api
melifera
util
tradit
medicin
treatment
rheumat
arthriti
skin
diseas
cancer
tumor
back
pain
billingham
et
al
son
et
al
due
antibacteri
antivir
antiinflammatori
effect
habermann
son
et
al
hwang
et
al
bio
activ
explain
varieti
compon
contain
bv
peptid
melittin
mlt
adolapin
apamin
mast
cell
degranul
peptid
sever
enzym
includ
phospholipas
biolog
activ
amin
histamin
epinephrin
nonpeptid
compon
carbohydr
lipid
free
amino
acid
larivier
melzack
park
et
al
son
et
al
howev
antivir
properti
bv
well
investig
also
mechan
fulli
understood
present
studi
investig
antivir
activ
bv
compon
envelop
nonenvelop
virus
includ
rna
dna
virus
vitro
attempt
understand
mechan
properti
mainli
owe
virucid
effect
bv
mlt
addit
evalu
antivir
activ
mlt
lethal
dose
pathogen
influenza
virus
mice
vivo
bv
mlt
suppli
chungjin
biotech
co
ltd
korea
compound
dissolv
phosphat
buffer
salin
pb
stock
solut
aliquot
store
human
embryon
kidney
atcc
tm
human
epitheli
cervix
adenocarcinoma
hela
atcc
ceropithecu
aethiop
epitheli
kidney
vero
atcc
human
epitheli
hela
contamin
carcinoma
atcc
tm
cani
familiari
kidney
epitheli
mdck
atcc
tm
cell
grown
maintain
dulbecco
modifi
eagl
medium
dmem
invitrogen
supplement
fetal
bovin
serum
fb
gibco
antibioticantimycot
solut
gibco
cell
cultur
incub
humidifi
atmospher
suppli
green
fluoresc
protein
gfp
fuse
vesicular
stomat
viru
vsvgfp
herp
simplex
viru
hsvgfp
propag
confluent
vero
cell
gfpfuse
coxsacki
viru
propag
confluent
hela
cell
gfpfuse
respiratori
syncyti
viru
rsvgfp
propag
cell
gfpfuse
influenza
challeng
virus
influenza
subtyp
propag
allanto
fluid
chicken
embryo
vsvgfp
rsvgfp
hsvgfp
virus
kindli
gift
dr
j
u
jung
depart
molecular
microbiolog
immunolog
univers
southern
california
usa
provid
dr
yk
choi
chunbuk
nation
univers
cheongju
republ
korea
cytotox
effect
bv
mlt
mdck
vero
hela
cell
monolay
determin
quantifi
cell
viabil
use
trypan
blue
exclus
test
describ
previous
strober
cell
grown
plate
confluent
monolay
differ
concentr
bv
mlt
ad
well
dilut
medium
without
sampl
use
control
experi
perform
triplic
plate
incub
humidifi
clarifi
cell
stain
trypan
blue
invitrogen
ratio
h
posttreat
hpt
mount
hemocytomet
obtain
percentag
viabl
cell
concentr
bv
mlt
plot
cell
viabil
cell
type
cytotox
bv
cell
type
express
cytotox
concentr
cc
concentr
cell
death
occur
rel
nontreat
control
cell
valu
bv
mlt
variou
envelop
nonenvelop
virus
determin
determin
ec
bv
mlt
hela
vero
mdck
cell
cultur
cellswel
plate
incub
co
atmospher
h
viral
suspens
coincub
differ
concentr
bv
mlt
min
inocul
cell
type
bv
mlt
moi
mdck
rsvgfp
hsvgfp
moi
vero
hela
moi
hela
ec
bv
mlt
vsvgfp
moi
test
vero
cell
respect
h
postinfect
hpi
cultur
medium
replac
fb
dmem
media
hpi
cell
supernat
harvest
viru
titer
evalu
describ
ec
valu
calcul
bv
mlt
concentr
yield
reduct
titer
compar
control
viru
infect
without
bv
mlt
experi
perform
triplic
determin
possibl
antivir
mechan
bv
three
differ
treatment
group
design
comparison
antivir
effect
bv
bv
pretreat
group
cell
pretreat
bv
h
infect
vsvgfp
similarli
unitsml
recombin
human
sigma
treat
posit
control
neg
control
dmem
medium
viru
infect
without
bv
treatment
use
bv
coincub
group
cell
inocul
mixtur
bv
vsvgfp
coincub
min
posttreat
group
viru
replic
inhibit
entri
cell
infect
vsvgfp
first
h
treat
bv
compar
antivir
effect
bv
vsvgfp
infect
level
viral
replic
reflect
gfp
express
photograph
magnif
hpi
vsvgfp
calcul
viru
titer
standard
plaqu
assay
modif
briefli
vero
cell
seed
cellswel
plate
h
cell
becam
confluent
monolay
harvest
cell
supernat
contain
replic
viru
serial
dilut
dilut
ad
fb
contain
well
media
well
replac
agar
overlay
hpi
day
later
number
plaqu
show
gfp
count
microscop
magnif
viru
titer
calcul
use
number
gfp
show
plaqu
dilut
factor
reed
muench
coil
miller
express
log
plaqu
form
unitml
log
pfuml
determin
whether
bv
could
induc
type
ifn
secret
level
measur
cell
supernat
bv
posit
control
dmem
medium
neg
control
treat
sampl
harvest
hpt
level
measur
use
commerci
human
elisa
kit
tfb
inc
accord
manufactur
protocol
determin
antivir
effect
bv
mlt
coincub
experi
carri
differ
virus
mlt
vsvgfp
bv
mlt
rsvgfp
hsvgfp
sever
cell
line
vero
hela
mdck
cell
cultur
cellswel
plate
incub
h
viral
suspens
vsvgfp
rsvgfp
hsvgfp
coincub
bv
mlt
min
incub
mixtur
inocul
specifi
cell
monolay
well
plate
vero
vsvgfp
hsvgfp
mdck
rsvgfp
use
dmem
supplement
fb
similarli
unitsml
virus
coincub
inocul
cell
posit
control
bv
antivir
activ
assay
dmem
medium
viru
infect
without
bv
mlt
treatment
use
neg
control
unabsorb
virus
residu
aspir
supernat
hpi
dmem
supplement
fb
residu
viru
infect
treat
sampl
reflect
gfp
express
photograph
magnif
hpi
cell
supernat
vsvgfp
rsvgfp
hsvgfp
cell
collect
hpi
express
gfp
quantifi
measur
gfp
absorb
use
glomax
detect
system
promega
viral
replic
level
calcul
standard
plaqu
assay
describ
viru
titer
consid
residu
infect
pfuml
evalu
virucid
activ
bv
mlt
differ
virus
test
bv
mlt
antivir
activ
test
hela
cell
virus
use
standard
antivir
activ
assay
viral
suspens
coincub
min
bv
mlt
incub
mixtur
inocul
h
cultur
monolay
hela
cell
plate
origin
seed
cellswel
rest
antivir
assay
procedur
similar
section
addit
bv
mlt
antivir
activ
determin
evalu
tissu
cultur
infect
dose
tcid
analysi
mrna
express
level
gene
residu
infect
titrat
sampl
collect
hpi
amount
viru
requir
produc
cytopath
effect
inocul
cell
describ
previous
express
log
moreov
gene
mrna
express
level
determin
hpi
total
mrna
cell
inocul
coincub
bv
mlt
extract
use
rneasi
mini
kit
qiagen
cdna
synthes
use
revers
transcriptas
toyobo
accord
manufactur
protocol
determin
mrna
express
level
gene
amplifi
use
gene
specif
primer
forward
primer
revers
primer
wen
et
al
gapdh
forward
primer
tgacca
revers
primer
gac
use
hous
keep
gene
seal
et
al
realtim
polymeras
chain
reaction
rtpcr
equal
amount
amplifi
product
run
ethidium
bromid
agaros
gel
visual
use
geldoc
imag
system
biorad
rel
gene
fragment
band
intens
rbi
compar
gapdh
use
band
quantif
softwar
biorad
find
effect
time
point
mlt
exhibit
virucid
activ
mlt
vsvgfp
coincub
min
mixtur
inocul
cell
monolay
well
plate
dmem
medium
viru
infect
without
mlt
treatment
use
neg
control
unattach
virus
mlt
aspir
supernat
hpi
dmem
supplement
fb
ad
well
virucid
effect
mlt
analyz
observ
gfp
express
magnif
hpi
gfp
absorb
viru
titer
quantifi
describ
earlier
section
determin
effect
mlt
viru
infect
possibl
effect
initi
stage
viral
replic
cycl
vitro
follow
treatment
group
design
viru
attach
assay
cotreat
mlt
simultan
ad
mdck
cell
residu
viru
mlt
aspir
supernat
hpi
replac
fb
dmem
media
entri
assay
posttreat
mdck
cell
infect
first
h
adsorpt
cell
wash
time
pb
remov
unattach
virus
treat
cell
dmem
fb
contain
mlt
dmem
medium
viru
infect
without
mlt
treatment
use
neg
control
effect
mlt
viru
attach
viru
entri
cell
determin
measur
gfp
express
hpi
use
glomax
multidetect
system
promega
viru
titer
determin
describ
method
section
express
pfuml
sediment
veloc
ultracentrifug
gastaminza
et
al
carri
delin
virucid
mechan
envelop
virus
sucros
gradient
separ
procedur
conduct
modif
identifi
fraction
contain
infecti
viral
particl
estim
size
molecular
mass
immonoblot
brief
discontinu
sucros
densiti
gradient
prepar
layer
success
decreas
sucros
densiti
solut
upon
one
anoth
polyallom
tube
discret
layer
sucros
visibl
mix
pb
mix
mlt
coincub
min
appli
top
tube
ultracentrifug
swing
bucket
rotor
beckman
rpm
h
ultracentrifug
without
disturb
sucros
layer
total
ml
fraction
assum
fraction
contain
viru
particl
collect
ml
gradient
brief
total
ml
gradient
ml
collect
ml
upper
layer
ml
lower
layer
sucros
gradient
fraction
nd
th
fraction
gradient
nd
th
fraction
denot
sequenti
fig
taken
immunoblot
use
polyclon
antibodi
deriv
viru
infect
mous
serum
identifi
fraction
contain
viru
particl
immunoblot
posit
control
pc
nativ
heat
min
prior
load
use
moreov
fraction
use
immunoblot
examin
infect
viru
particl
observ
measur
gfp
express
hpi
infect
mdck
cell
anim
studi
conduct
appropri
condit
approv
institut
anim
care
use
committe
biolead
corpor
daejeon
south
korea
protocol
number
treatment
challeng
experi
conduct
approv
laboratori
facil
studi
mous
model
chosen
determin
whether
mlt
exhibit
antivir
protect
vivo
mice
surviv
rate
bodi
weight
evalu
challeng
coincub
mixtur
pb
mlt
influenza
viru
subtyp
whole
experi
femal
mice
g
use
surviv
rate
analysi
mice
divid
group
treat
control
treat
lung
viru
titrat
anoth
mice
group
group
treat
first
mlt
ng
coincub
minimum
lethal
dose
mld
min
mixtur
intranas
administ
per
mice
ngg
bodi
weight
bodi
weight
surviv
rate
note
day
postinfect
dpi
mice
show
bodi
weight
loss
consid
experiment
end
point
human
kill
lung
tissu
collect
asept
euthan
mice
dpi
homogen
equal
volum
mlg
pb
contain
antibioticantimycot
solut
sampl
centrifug
g
min
supernat
immedi
serial
dilut
inocul
cultur
mdck
cell
grown
confluenc
well
tissu
cultur
plate
lung
viral
titer
calcul
reed
muench
method
express
tcid
lung
statist
analysi
perform
use
graphpad
prism
softwar
version
window
graphpad
softwar
vitro
assay
carri
triplic
data
express
mean
standard
deviat
sd
differ
group
analyz
analysi
varianc
anova
student
ttest
comparison
surviv
done
logrank
test
use
graphpad
prism
version
p
regard
signific
differ
concentr
bv
test
cell
type
use
studi
determin
whether
bv
cytotox
cell
cc
bv
mlt
vitro
present
tabl
shown
bv
hela
mdck
cell
respect
repres
cell
viabl
concentr
cell
lowest
valu
bv
obtain
among
test
cell
line
follow
vero
cell
cytotox
concentr
mlt
also
test
via
tryphan
blue
stain
cc
mlt
vero
mdck
hela
cell
respect
accord
valu
mlt
dose
show
cell
viabil
select
experi
low
mlt
dose
vero
mdck
cell
low
mlt
dose
hela
cell
ec
bv
mlt
vitro
present
tabl
ec
valu
bv
vsvgfp
rsvgfp
hsvgfp
respect
viru
replic
inhibit
concentr
moreov
ec
mlt
approxim
vsvgfp
rsvgfp
hsvgfp
respect
data
demonstr
bv
vsvgfp
lower
ec
valu
mlt
moreov
bv
exhibit
higher
select
index
si
mlt
vsvgfp
tabl
consid
effect
cytotox
bv
mlt
use
subsequ
vitro
antivir
assay
util
dose
mention
method
section
appropri
could
suggest
antivir
activ
bv
mlt
virus
examin
result
cytotox
peptid
test
cell
determin
antivir
activ
understand
possibl
antivir
mechan
bv
three
differ
treatment
conduct
vsvgfp
viru
cell
de
cribe
materi
method
bv
pretreat
h
infect
vsvgfp
cell
viruspeptid
pretreat
show
signific
reduct
viru
replic
hpi
pattern
compar
pretreat
compar
vsvgfp
infect
cell
fig
moreov
level
measur
bv
treat
cell
supernat
fig
bv
significantli
induc
higher
level
secret
compar
control
medium
similar
pattern
observ
treat
cell
supernat
thu
data
indic
bv
mediat
antivir
innat
immun
respons
epitheli
cell
trigger
express
type
ifn
may
stimul
antivir
state
cell
shown
fig
bv
coincub
vsvgfp
min
inocul
cell
viruspeptid
coincub
also
show
promin
reduct
viru
titer
hpi
compar
vsvgfp
infect
cell
although
low
degre
cell
infect
vsvgfp
treat
bv
posttreat
hpi
also
show
inhibit
viru
replic
hpi
fig
bv
posttreat
cell
show
similar
viru
titer
especi
hpi
significantli
lower
vsvgfp
infect
cell
base
three
treatment
mode
carri
specul
antivir
activ
bv
attribut
stimul
type
ifn
signal
virucid
activ
abil
inhibit
viru
replic
viru
enter
cell
investig
antivsv
efficaci
bv
effect
envelop
virus
investig
rsvgfp
hsvgfp
coincub
bv
min
inocul
cell
viruspeptid
coincub
show
reduct
viru
infect
fig
bv
treat
fig
rsvgfp
fig
hsvgfp
fig
show
distinct
reduct
gfp
express
respect
viru
titer
respect
hpi
compar
untreat
viru
infect
group
suggest
bv
could
disrupt
infect
broad
spectrum
envelop
virus
convinc
virucid
effect
gfp
express
level
measur
gloma
multi
dectect
luminomet
promega
viru
titer
determin
standard
plaqu
assay
viru
titer
express
mean
sd
scale
bar
error
bar
indic
rang
valu
obtain
triplic
three
independ
experi
p
p
indic
signific
differ
group
compar
student
ttest
investig
differ
antivir
effect
bv
sever
compound
bv
test
find
compon
bv
respons
virucid
effect
among
mlt
show
similar
effect
bv
confirm
virucid
effect
mlt
envelop
rna
vsvgfp
rsvgfp
dna
hsvgfp
virus
test
test
cell
direct
effect
mlt
viru
show
reduc
viru
infect
fig
differ
viral
suspens
coincub
mlt
min
inocul
cell
show
mark
reduct
gfp
express
hpi
wherea
untreat
viru
infect
group
show
significantli
high
level
gfp
express
vsvgfp
fig
fig
rsvgfp
fig
hsvgfp
fig
relat
mlt
treat
group
show
reduc
viral
supernat
titer
vsvgfp
rsvgfp
hsvgfp
compar
viru
infect
group
collect
suggest
mlt
antivir
activ
virucid
effect
broad
spectrum
envelop
virus
identifi
bv
virucid
effect
broad
spectrum
envelop
virus
efficaci
nonenvelop
rna
virus
also
evalu
viral
suspens
coincub
min
bv
mixtur
bv
inocul
mono
gene
mrna
express
evalu
use
gene
specif
pcr
primer
sampl
normal
use
gapdh
rbi
gene
gapdh
determin
use
geldoc
imag
system
band
quantif
softwar
c
f
viru
titer
express
mean
sd
scale
bar
error
bar
indic
rang
valu
obtain
triplic
three
independ
experi
p
p
indic
signific
differ
group
compar
student
ttest
layer
hela
cell
hpi
mark
reduct
gfp
express
observ
treat
cell
compar
untreat
cell
fig
relat
significantli
lower
viru
titer
detect
treat
cell
infect
cell
fig
compar
viru
titer
treat
cell
moreov
induc
cpe
markedli
inhibit
cell
viabil
higher
treat
cell
infect
group
data
shown
infect
cell
show
significantli
higher
tcid
treat
cell
fig
mrna
express
level
decreas
treat
cell
compar
infect
cell
fig
exhibit
lower
rbi
gene
interestingli
mlt
coincub
also
show
lower
gfp
express
viru
titer
comparison
infect
cell
fig
exhibit
signific
reduct
cpe
high
cell
viabil
treat
cell
infect
group
data
shown
addit
infect
cell
show
significantli
higher
treat
cell
fig
moreov
mrna
express
level
decreas
treat
cell
compar
infect
cell
fig
exhibit
lower
rbi
gene
collect
data
demonstr
bv
mlt
exert
virucid
antivir
activ
envelop
virus
also
nonenvelop
virus
gfp
express
level
measur
gloma
multi
dectect
luminomet
promega
viru
titer
determin
standard
plaqu
assay
viru
titer
express
mean
sd
scale
bar
error
bar
indic
rang
valu
obtain
triplic
three
independ
experi
p
p
indic
signific
differ
group
compar
student
ttest
determin
effect
time
need
mlt
act
viru
mlt
incub
moi
vsvgfp
differ
time
shown
fig
infect
vsvgfp
dramat
suppress
increas
time
min
incub
viru
infect
initi
reduc
min
incub
min
incub
show
high
virucid
effect
similar
previou
data
suggest
mlt
inactiv
inhibit
viru
replic
even
contact
viru
short
period
time
inactiv
infect
understand
effect
mlt
viral
replic
cycl
viruscel
attach
virusentri
assay
perform
shown
fig
gfp
absorb
viru
titer
mlt
treat
group
significantli
differ
compar
control
viru
infect
attach
entri
assay
result
indic
mlt
could
interfer
initi
step
viru
life
cycl
unabl
inhibit
viru
infect
replic
viru
infect
cell
evid
data
mlt
involv
step
occur
prior
viruscel
attach
mainli
may
direct
interact
viru
mlt
turn
inhibit
viru
infect
clarifi
virucid
activ
mlt
envelop
virus
sediment
veloc
ultracentrifug
conduct
use
continu
sucros
gradient
virus
coincub
pb
mlt
subject
immunoblot
describ
materi
method
shown
fig
surfac
viral
protein
hemagglutinnin
ha
nucleoprotein
np
neuraminidas
na
coincub
pb
detect
sucros
virucid
mechan
studi
mlt
sediment
veloc
ultracentrifug
viru
coincub
pb
mlt
min
sampl
load
top
continu
sucros
densiti
gradient
place
ultracentrifug
rotor
rpm
h
fraction
collect
nd
th
fraction
six
layer
sucros
gradient
subject
immunoblot
nd
th
fraction
number
sequenti
viral
protein
ha
na
np
contain
fraction
detect
use
polyclon
antibodi
deriv
viru
infect
mous
serum
nativ
load
immunoblot
posit
control
pc
b
c
fraction
use
immunoblot
examin
infect
viru
particl
observ
measur
gfp
express
hpi
infect
mdck
cell
gfp
imag
obtain
fluoresc
microscopi
magnif
gfp
express
level
measur
gloma
multi
dectect
luminomet
promega
gfp
express
level
express
mean
sd
scale
bar
error
bar
indic
rang
valu
obtain
triplic
three
independ
experi
p
p
indic
signific
differ
group
compar
student
ttest
cushion
center
fraction
number
correspond
protein
band
size
posit
control
pc
contrast
protein
coincub
mlt
observ
mainli
upper
sucros
gradient
fraction
sucros
cushion
number
follow
slightli
fraction
number
suggest
structur
destabil
occur
due
mlt
howev
effect
viru
structur
protein
moreov
virus
treat
pb
fraction
sucros
cushion
show
high
viru
infect
vitro
howev
virus
coincub
mlt
show
infect
sucros
cushion
fig
c
cell
treat
fraction
sucros
cushion
weakli
infect
probabl
due
remain
intact
viru
particl
interact
mlt
mass
differ
nativ
mlt
coincub
fraction
demonstr
mlt
direct
effect
structur
destabil
viru
particl
thu
interrupt
viru
infect
evalu
efficaci
mlt
vivo
mlt
incub
min
mixtur
inocul
intranas
monitor
daili
morbid
toxic
observ
treat
mice
indic
weight
loss
fig
surviv
fig
treat
mice
show
slightli
decreas
bodi
weight
dpi
regain
weight
dpi
wherea
treat
mice
exhibit
sever
weight
loss
mixtur
coincub
min
intranas
administr
sixweekold
femal
mice
gmous
bodi
weight
surviv
rate
b
monitor
dpi
group
lung
tissu
infect
mice
collect
dpi
viral
load
lung
measur
standard
plaqu
assay
group
c
p
indic
signific
differ
group
compar
student
ttest
mice
succumb
infect
start
die
dpi
show
bodi
weight
loss
die
dpi
moreov
control
group
mice
exhibit
sever
respiratori
diseas
clinic
sign
decreas
activ
hunch
postur
huddl
ruffl
fur
mlt
treat
mice
show
increas
protect
bodi
weight
clinic
sign
indic
mlt
protect
mice
lethal
viru
infect
moreov
influenza
viru
transmit
mainli
respiratori
system
mice
replic
effici
lung
bouvier
lowen
lung
titer
evalu
treat
mice
treat
mice
show
lower
lung
viral
titer
treat
mice
log
tcid
dpi
fig
result
indic
mlt
abil
inhibit
viral
replic
lethal
infect
influenza
virus
anim
venom
deriv
potenti
natur
agent
innov
drug
develop
sever
diseas
howev
mani
compon
function
fulli
unexplor
bv
cocktail
natur
peptid
divers
biolog
activ
henc
bv
compon
gain
interest
consid
valuabl
resourc
use
drug
design
develop
studi
potenti
antivir
activ
bv
vsvgfp
viru
infect
first
evalu
use
pretreat
coincub
posttreat
experi
fig
interestingli
bv
inhibit
replic
vsvgfp
experi
among
three
differ
mode
antivir
activ
bv
studi
mainli
focus
antivir
effect
bv
coincub
experi
bv
mainli
constitut
mlt
biolog
activ
amin
apamin
adolapin
divers
peptid
nonpeptid
compon
habermann
larivier
melzack
park
et
al
son
et
al
thu
investig
antivir
activ
bv
main
constitu
use
coincub
experi
result
found
mlt
compound
show
similar
effect
bv
data
shown
mlt
constitut
almost
dri
bv
cation
peptid
hemolyt
activ
human
erythrocyt
tosteson
et
al
eukaryot
cell
broad
antimicrobi
spectrum
due
abil
disrupt
lipid
cell
membran
habermann
tosteson
et
al
mlt
rapidli
bind
human
red
blood
cell
alreadi
sub
micromolar
concentr
induc
releas
hemoglobin
increas
membran
permeabl
final
lyse
cell
degrado
et
al
mlt
disrupt
cell
membran
kill
gramneg
gramposit
bacteria
micromolar
concentr
rang
maher
mcclean
besid
power
antimicrobi
lytic
activ
mlt
exhibit
varieti
biolog
effect
mlt
hinder
transport
pump
h
k
atpas
cuppoletti
et
al
na
k
atpas
cuppoletti
abbott
acceler
permeabl
cell
membran
ion
induc
inhibit
aggreg
membran
protein
clagu
cherri
mahaney
thoma
also
mlt
stimul
activ
phospholipas
kuchinka
seelig
furthermor
mlt
could
interfer
activ
cellular
enzym
na
k
atpas
respons
membran
fusion
process
suppress
cell
fusion
mediat
syncyti
mutant
baghian
kousoula
matan
castilla
specul
broad
spectrum
antivir
action
might
due
abil
mlt
affect
ion
gradient
across
cell
membran
previou
studi
also
show
mlt
display
antivir
activ
anim
plant
virus
murin
retrovirus
esser
et
al
waching
et
al
waching
et
al
baghian
et
al
tobacco
mosaic
viru
tmv
marco
et
al
nevertheless
mechan
mlt
activ
fulli
discov
case
studi
antivir
effect
mlt
examin
broad
spectrum
virus
mlt
exhibit
antivir
activ
envelop
virus
influenza
viru
vesicular
stomat
viru
vsv
respiratori
syncyti
viru
rsv
herp
simplex
viru
hsv
addit
mlt
also
inhibit
replic
nonenvelop
virus
coxsacki
viru
base
data
viru
infect
cell
decreas
incub
time
viru
mlt
increas
attach
entri
assay
mlt
unabl
inhibit
viru
infect
replic
fig
veloc
sediment
ultracentrifug
follow
immunoblot
convinc
mass
coincub
mlt
reduc
compar
nativ
fig
consequ
could
suggest
antivir
activ
mlt
mainli
occur
due
involv
direct
interact
viru
surfac
direct
effect
may
involv
destabil
viru
structur
inactiv
viral
particl
virucid
activ
interrupt
viru
infect
result
suggest
mlt
may
bind
viru
surfac
envelop
viru
surfac
charg
interact
viru
decreas
infect
virus
li
et
al
previous
esser
et
al
show
antivir
activ
mlt
attribut
direct
lysi
viral
membran
demonstr
murin
retrovirus
although
electron
microscopi
crystal
structur
analysi
mlt
interact
viral
membran
conduct
studi
previou
inform
mlt
crystal
structur
analysi
bio
physic
properti
ahel
amphipath
hydrophob
cation
dempsey
could
assum
mlt
may
also
abl
interact
phospholipid
bilay
viral
envelop
caus
alter
lipid
organ
membran
report
hemolysi
degrado
et
al
terwillig
et
al
form
ionperm
channel
way
voltag
gate
pore
tosteson
et
al
micel
disc
format
membran
could
diffus
cell
content
hole
produc
dufourc
et
al
dufourc
et
al
howev
exact
mechan
involv
yet
identifi
need
elucid
futur
studi
moreov
one
interest
data
obtain
studi
mlt
inactiv
envelop
virus
also
nonenvelop
virus
coxsacki
viru
howev
mlt
effect
constitu
viru
extend
virucid
activ
mechan
nonenvelop
virus
need
investig
detail
addit
apart
virucid
activ
bv
found
pretreat
posttreat
bv
inhibit
viru
replic
especi
pretreat
experi
demonstr
bv
could
induc
type
ifn
secret
cell
fig
data
suggest
bv
mediat
antivir
respons
epitheli
cell
trigger
antivir
state
play
crucial
role
inhibit
viral
replic
moreov
posttreat
experi
bv
also
show
inhibit
vsvgfp
replic
howev
mlt
show
induct
type
ifn
data
shown
result
could
assum
biolog
activ
compon
present
bv
mlt
inhibit
specif
viral
replic
step
vsv
consequ
could
expect
bv
specif
compound
bv
might
play
role
viral
replic
step
variou
innat
immun
pathway
involv
bv
antivir
activ
especi
stimul
type
ifn
signal
howev
mlt
effect
stimul
type
ifn
detail
relationship
mechan
antivir
effect
bv
activ
compound
present
identifi
yet
bv
investig
cytotox
peptid
one
main
difficulti
rise
clinic
usag
therapeut
peptid
henc
cytotox
evalu
bv
mlt
exhibit
rang
test
cell
tabl
could
suggest
data
antivir
activ
bv
mlt
virus
examin
result
cytotox
peptid
test
cell
vivo
studi
also
show
toxic
sign
mous
challeng
experi
fig
mice
protect
lethal
infect
influenza
viru
suggest
mlt
use
safe
antivir
agent
broad
spectrum
virus
maximum
efficaci
depend
cell
type
howev
safeti
concern
mechan
action
need
elucid
detail
futur
summari
studi
demonstr
bv
mlt
deriv
bv
exhibit
potent
antivir
activ
variou
envelop
nonenvelop
virus
vitro
influenza
viru
vivo
mous
model
moreov
antivir
mechan
confirm
involv
direct
interact
viral
surfac
apart
bv
virucid
activ
bv
stimul
type
ifn
subsequ
could
stimul
antivir
state
host
cell
also
inhibit
viral
replic
taken
togeth
result
suggest
bv
mlt
potenti
becom
prophylact
therapeut
agent
infecti
viral
diseas
md
bashir
uddin
byeonghoon
lee
design
execut
viru
infect
experi
chamilani
nikapitiya
jaehoon
kim
taehwan
kim
hyuncheol
lee
execut
cell
biolog
experi
choul
goo
kim
jongsoo
lee
analyz
data
jongsoo
lee
chuljoong
kim
design
overal
studi
wrote
paper
anim
experi
approv
institut
anim
care
use
committe
biolead
corpor
refer
perform
accord
guid
care
use
laboratori
anim
us
nation
institut
health
none
author
financi
person
relationship
peopl
organ
could
inappropri
influenc
bia
studi
